đ° Planegg News
Page 38 - Planegg News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planegg. Real-time updates on events, politics, business and more.
January 24, 2022
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous24.01.2022 / 22:01 The issuer is solely responsible for the content of this announcement.MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index ReportMorphoSys AG (FSE: MOR; NASDAQ: MO...
January 18, 2022
Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( ⏠66.9 million)Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 millionPLANEGG / MUNICH, GERMANY / ACCESSWIRE
January 10, 2022
Press release content from Accesswire. The AP news staff was not involved in its creation.
January 10, 2022
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40
December 20, 2021
PressNetwork â Presseportal fĂźr Pressemitteilungen und Unternehmens-News
December 12, 2021
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosisData presented during poster and oral sessions at the 63rd American
November 30, 2021
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous29.11.2021 / 22:02 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 29, 2021MorphoSys AG: Corporate Calendar 2022 Dear Madam/Sir,Please note MorphoSys' financial reporting dates 2022 as follow...
November 29, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022Dear Madam/Sir,Please note MorphoSys' financial reporting dates 2022 as follows:Publication of Interim Statement / ReportConference
November 4, 2021
Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathyPLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4
November 2, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to âŹ